Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.06.19
Views: 1201

Dr Enriqueta Felip - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain

Dr Enriqueta Felip speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the preliminary results from a phase II study examining the combination of bemcentinib and pembrolizumab in patients with advanced NSCLC.

She reveals that a 35 percent response rate was achieved in those patients with AXL-positive tumours. For patients with PD-L1 negative tumours, a response rate of 20 percent was seen.

Dr Felip also discusses the main adverse events associated with this combination, which included grade 3 liver toxicity - but improved with the use of steroids.

For the future, Dr Felip mentions that this particular combination may have a role specifically for patients who have been selected by AXL.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation